FM
fazen.markets
healthcare·esfritzh

Aprea WEE1 Data: Two PRs in 56 Patients, Dose Expansion Set

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

aprea-therapeuticsapr-1051wee1-inhibitoracesot-1051phase-1-oncology

Key Takeaways

  • 1Aprea's WEE1 signal is real but thin, and the company is now betting the program on biomarker-selected uterine and ovarian cancers.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Aprea Therapeutics (Nasdaq: APRE) reported interim Phase 1 results on 20 November 2026 for its oral WEE1 inhibitor APR-1051, with two RECIST 1.1 partial responses among 43 response-evaluable patients and at least 50% reductions in the pharmacodynamic marker pCDK1-Y15 in 21 of 25 evaluable paired skin biopsies. The company said 56 patients had received the drug across all dose levels as of a 1 November 2026 cutoff. One dose-limiting toxicity was observed. The data were presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium in Barcelona.

Context — why these Phase 1 numbers matter now

The report gives its own comparison: longer follow-up on previously reported clinical activity. Aprea said the interim dataset supports continued dose optimization and once-daily dosing, and that the confirmed response was still ongoing beyond 10 months of treatment at cutoff.

The backdrop is a crowded early-stage oncology field where single-agent response rates in heavily pre-treated solid tumors are typically low. What matters for a clinical-stage company is whether a signal is durable and whether a biomarker can select the patients who produce it. Aprea is betting on both.

The trigger for the update is the conference presentation by lead investigator Timothy A. Yap of The University of Texas MD Anderson Cancer Center, which bundled clinical activity, target engagement, safety and pharmacokinetics into one disclosure.

The company also said it is refining enrollment rather than broadening it. It is working with a diagnostics partner on an immunohistochemistry assay for cyclin E overexpression, and expanding the trial to more than 10 clinical sites from the nine previously disclosed. Those are the operational changes that follow the data.

Aprea frames APR-1051 as differentiated by design: an oral, selective small-molecule WEE1 inhibitor built to minimize off-target inhibition of the PLK family of kinases. The company said that potential differentiation remains under clinical evaluation, which is the honest status of any Phase 1 compound.

Data — what the numbers show

The clinical picture rests on a small denominator. Of 56 enrolled patients, 43 were evaluable for response. Two patients with PPP2R1A-mutated uterine cancers achieved partial responses, one confirmed and one unconfirmed. The confirmed response came in a patient with uterine carcinosarcoma treated at 220 mg. Sixteen patients had stable disease as best overall response, five of them lasting four months or longer. Thirteen patients were still awaiting initial on-treatment imaging at cutoff.

MeasureResult
Patients treated56
Response-evaluable43
Confirmed + unconfirmed PRs2
Stable disease 4+ months5
pCDK1-Y15 reduction ≥50%21 of 25 (84%)
Dose-limiting toxicities1 of 56

Safety leaned manageable at this stage. The single DLT was AST and ALT elevation without bilirubin elevation in a patient with known liver metastases at the 50 mg dose. Grade 3/4 neutrophil count decrease occurred in 4 patients (7%), all at 300 mg, with no febrile neutropenia. Two patients (4%) had Grade 3 pneumonitis, both serious. Other Grade ≥3 treatment-related events included fatigue (5%), lymphocyte count decrease (4%), dyspnea (2%) and diarrhea (2%). All-grade nausea reached 41%, fatigue 25%, diarrhea and vomiting 14% each.

Pharmacokinetics showed exposure rising with once-daily dosing through 300 mg and a median half-life of roughly 18 hours, which the company said supports once-daily administration. Dose escalation was modified to add 250 mg and 350 mg levels, and Part 1 now allows up to 110 patients. The previously disclosed 400 mg and 500 mg levels remain under evaluation.

Analysis — what it means for markets and sectors

Aprea's read is that WEE1 inhibition may be most therapeutically relevant in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. That is a narrowing of the funnel, and it changes which competitors matter. Any developer running a WEE1 program in these tumor types is now watching the same biology, though the report names none and gives no comparative efficacy figures.

The counter-argument is straightforward. Two responses in 43 evaluable patients, one of them unconfirmed, is a signal, not a rate. The confirmed response came at 220 mg while the Grade 3/4 neutropenia clustered at 300 mg, so the therapeutic window is still being mapped. Pneumonitis at 4% is a class-watch item for any DNA-damage-response agent.

A limitation the report itself implies: the pharmacodynamic evidence comes from paired skin punch biopsies, a surrogate tissue, not from tumor. Target engagement in skin does not guarantee engagement in tumor, which is why the expansion cohorts carry the real evidentiary burden.

Positioning follows the calendar. This is a binary-risk, pre-revenue biotech where flow is driven by data readouts rather than earnings. Investors holding through the dose-selection stage are underwriting the expansion cohorts, not the Phase 1 dataset.

Outlook — what to watch next

Aprea said completion of dose escalation and backfill expansion enrollment is expected in the second quarter of 2027. That is the next hard date the company has given.

Before then, watch the two operational milestones. Enrollment of at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer is the target, and the cyclin E IHC assay from the diagnostics partner is the gate on identifying those patients. A validated assay is what turns a biomarker hypothesis into an enrollment funnel.

Part 2 is a separate stage: up to 80 patients randomized 1:1 between two selected doses to determine the recommended Phase 2 dose. The transition from Part 1 to Part 2 is the decision point that matters, and the dose levels now in play — 250 mg and 350 mg, alongside the 400 mg and 500 mg levels under evaluation — define the range.

The report gives no share price, no cash balance and no financing terms. Readers asking what the data are worth in market terms will have to wait for disclosure the company has not made.

Frequently Asked Questions

What is APR-1051 and how does it work?

APR-1051 is an investigational oral small-molecule inhibitor of WEE1, a kinase that regulates cell cycle checkpoints and helps cancer cells respond to DNA damage. Aprea designed it to minimize off-target inhibition of the PLK family of kinases, aiming at a better therapeutic profile. The company said that differentiation remains under clinical evaluation. It is being tested as a single agent, given once daily in 28-day cycles, in the Phase 1 ACESOT-1051 study registered as NCT06260514.

What did the safety data show in the Phase 1 trial?

Among 56 treated patients, one dose-limiting toxicity occurred: AST and ALT elevation without bilirubin elevation in a patient with known liver metastases at 50 mg. Grade 3/4 neutrophil count decrease appeared in 4 patients (7%), all at 300 mg, with no febrile neutropenia. Two patients (4%) had serious Grade 3 pneumonitis. The most common all-grade events were nausea (41%), fatigue (25%), diarrhea (14%) and vomiting (14%).

Which patients will the trial enroll next?

Aprea plans to enroll at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing, platinum-resistant ovarian cancer as dose escalation and backfill expansion continue. It is also expanding to more than 10 clinical sites and working with a diagnostics partner on a cyclin E immunohistochemistry assay. The company said it expects dose escalation and backfill expansion enrollment to complete in the second quarter of 2027.

Bottom Line

Aprea's WEE1 signal is real but thin, and the company is now betting the program on biomarker-selected uterine and ovarian cancers.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related